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Abstract
Objective—There have been no prospective large-scale studies to evaluate the prevalence and
determinants of Barrett’s esophagus (BE) in children who are free from neurodevelopmental
disorders and tracheoesophageal abnormalities.
Design—A prospective cross-sectional study
Setting—Three pediatric GI Centers in Houston, TX, Phoenix AZ, and Portland ME between
February, 2006 and December, 2007.
Patients—Children and adolescents consecutively presenting for elective upper endoscopy.
Patients with neurodevelopmental and tracheoesophageal disorders were excluded.
Interventions—Endoscopic pictures of all cases with suspected BE were independently
reviewed and verified by 2 experienced investigators. Esophageal biopsies were obtained in all
patients, and targeted biopsies were also obtained from suspected BE.
Main Outcome Measurements—Endoscopically suspected BE and histologically confirmed
BE.
Results—A total of 840 patients (mean age, 9.5 years) were enrolled and had complete
questionnaire and endoscopic data. Twelve patients were suspected of having BE (prevalence of
1.43% (95% CI: 0.73–2.45)) and only 1 patient has intestinal metaplasia for a prevalence of 0.12%
(95% CI 0–0.65), while the rest had gastric (n=6) or squamous (n=5). Patients with suspected BE
had higher mean BMI (23.0 vs. 19.1, p=0.05) and more chest pain (50% vs. 13%, p<0.01) than
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patients without BE or reflux esophagitis. There was a trend of higher frequency of dysphagia,
heartburn and regurgitation in patients with suspected BE.
Limitations—The accuracy of BE prevalence estimates is limited by the small number of cases.
Conclusions—BE is rare in children without neurodevelopmental delay or tracheoesophageal
anomalies presenting for elective upper endoscopy.
Introduction
Gastroesophageal reflux (GER) is considered physiologic in infants and usually
spontaneously resolves by 18–24 months of age.1, 2 GER in older children is considered
pathologic and consistent with gastroesophageal reflux disease (GERD) .3–6 In particular,
reflux disorders in older children may become chronic, and may be associated with
esophageal and extraesophageal disorders. GERD symptoms occur in an estimated 2% to
8% of children aged 3–18 years.7 The endoscopic manifestations of GERD include reflux
esophagitis (RE) and Barrett’s esophagus (BE).1 There is little information on the
endoscopic manifestations of pediatric GERD based on prospective data with standardized
of endoscopic recordings and biopsies.
BE in children has been examined in retrospective studies, consisting of case series and
cross-sectional studies. Hassall et al. conducted a meta review of case reports and small case
series described a total of 119 reported cases of BE in children, of whom only 36% had
intestinal metaplasia.8 This review did not evaluate prevalence of BE because the
appropriate denominator was missing from most reports. We have conducted several studies
geared towards estimating the prevalence of BE in children. In a single center cross-
sectional study examining the prevalence of endoscopic manifestations of GERD in 402
neurologically normal children without esophageal congenital abnormalities, the prevalence
of suspected BE was 2.7% and none of these cases was confirmed by histologic
examination. In the same study, endoscopically visible RE was found in 34.6%.5 In another
retrospective multicenter cross-sectional study using Pediatric Clinical Outcomes Research
Initiative (PEDS-CORI) database, only 17 of 6731 (0.25%) children had suspected BE.9
Using the same data source, Gilger et al. found 888 of 7188 patients (12.4%) who
underwent endoscopy were reported to have RE.10 The limitations of these studies included
the variations of endoscopic interpretation and the absence of histologic findings for RE. In
addition, the PEDS-CORI studies contained an undefined number of children with
congenital disorders and tracheoesophageal disorders thus limiting its generalizability to the
vast majority of children with GERD who do not have these comorbidities. Furthermore,
given the retrospective nature of these studies, there was a lack of standardization of
endoscopic recordings and biopsies.11
In this study, we examine the prevalence of BE as well as RE as defined by endoscopic and
histologic criteria in a prospective, multicenter setting in normal children without
neurodevelopmental or tracheoesophageal disorders.
Methods
Study Design and Study Population
We conducted a prospective cross-sectional study among children and adolescents
presenting during 2006–2007 for upper endoscopy in three pediatric centers (Texas
Children’s Hospital, Houston, Texas; Phoenix Children’s Hospital, Phoenix, Arizona; and
Barbara Bush Children’s Hospital, Portland, Maine). Consecutive patients less than 18 years
of age who were referred to endoscopy for non-urgent indications were recruited for the
study. We excluded patients with cerebral palsy, congenital or post operative esophageal
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stricture, tracheoesophageal fistula, and mental retardation. Before endoscopy, patients or
their legal guardians completed a standardized questionnaire that assessed for the presence,
duration, and frequency of upper gastrointestinal symptoms (aspiration, chest pain,
dysphagia, epigastric pain, heartburn, regurgitation, vomiting, and poor weight gain) and
possible risk factors for GERD or BE (tube feeding, cerebral palsy, esophageal stricture,
fundoplication, mental retardation, or tracheoesophageal fistula). We obtained same-day
weight (kilograms) and height (meters) before endoscopy using a calibrated scale and
stadiometer.
Endoscopy
Suspected BE was defined by any length of visible pink mucosa in the tubular esophagus
above the proximal end of the gastric folds. For these cases, the length of circumferential
areas of BE and the number and length of BE tongues were measured according to the
Prague C and M grading system.12, 13 The presence and severity of erosive esophagitis seen
on endoscopy were graded according to the Los Angeles (LA) Classification (grade A–D).14
The presence of hiatal hernia, nodularity, and ulceration in the esophagus were also
systematically recorded.
To ensure standardization of study endoscopy report, the principal investigator (MG)
conducted orientation sessions with all endoscopists involved in the study. These involved
both live as well as picture demonstration and agreement on landmarks of gastroesophageal
endoscopic findings. All endoscopists were required to provide endoscopic photograph of
the gastroesophageal junction (GEJ) area including the squamocolumnar junction in all
procedures. The endoscopists involved were not limited to members of the investigative
team. Every 4 months, a sample of 10 photographs , including all suspected BE, of the GEJ
area from each endoscopist were reviewed by the PI/co PI, both of whom were blinded to
the findings of the endoscopic report (presence/absence of suspected BE). If a discrepancy
between the endoscopist and the PI/coPI exceeded 20%, another training session was
conducted with that endoscopist.
Esophageal Biopsies and Histopathology
Esophageal biopsies were obtained in all cases at 2–3 cm above the squamocolumnar
junction and in suspected BE cases, four-quadrant biopsies for every 1 cm of suspected
circumferential BE tissue and biopsies from any tongues were also obtained. We did not
require taking a biopsy of the squamocolumnar junction. All biopsies were reviewed by
local pathologist at each of the 3 institutions. All mucosal biopsies from suspected BE were
subsequently examined and graded by one gastrointestinal pathologist blinded to the
endoscopic finding and risk factors. Cases of definite BE were defined as endoscopic
presence of any visible length of pink mucosa in the esophagus combined with histological
presence of goblet cells in biopsies taken from these areas. Cases of RE were defined as
endoscopic erosion according to the LA classification or reflux esophagitis on
histopathology, which is defined as biopsy showing reactive epithelial changes with
hyperplasia of the basal cell layer, elongation of vascular papillae, and increase infiltration
of inflammatory cells.15 We excluded 19 patients with possible eosinophilic esophagitis as
defined by the histological presence of greater than 15 eosinophils per high power field
irrespective of symptoms.
The study protocol was approved by the Institutional Review Board (IRB) at the three
institutions and informed consent was obtained from parents of study subjects.
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The prevalence rate (and 95% confidence intervals) of suspected BE, definite BE, or RE
were calculated by dividing the number of patients with these conditions by the total number
of patients in the study with complete historical, endoscopic, and histological data. Potential
risk factors or associated symptoms were analyzed for suspected BE (vs. no BE or RE) and
RE (vs. no BE or RE) using chi-square tests or Fisher’s exact test for categorical variables
and ANOVA for continuous variables. Logistic regressions were used to estimate odds
ratios and their accompanying 95% confidence intervals.
Results
Between February 2006 and December 2007, a total of 840 patients were enrolled with
complete questionnaire and endoscopic data. Of those patients, 570 were from Texas
Children’s Hospital, 146 were from Phoenix Children’s Hospital, and 124 were from
Barbara Bush Children’s Hospital. The mean age of enrolled patients was 9.5 (SD: 5.3)
years. Twelve patients were suspected of having BE thus giving a prevalence of 1.41%
(95% CI: 0.73–2.45). Six of the suspected BE were C0M1, two C0M1.5, two C0M1.5, one
C0M2 and one C0.5M1.5 on the Prague classification where C refers to circumferential
length and M refers to maximum length in centimeters 13. The level of agreement on
suspected BE among the endoscopist, PI and co PI was 100%. Only 1 patient (14 years old)
with suspected BE had intestinal metaplasia in biopsy obtained from suspected BE areas
(Figure 1) thus giving a prevalence of 0.12% (95% CI: 0–0.65); the indication for endoscopy
in that child was nausea and vomiting unresponsive to PPI. The rest of the patients with
suspected BE had gastric oxyntic glands (n=6) or squamous (n=5) esophageal epithelium
and no goblet cells on histologic examinations of biopsies obtained from suspected BE.
The mean age of patients with suspected BE was significantly different than those without
BE or RE (11.3 vs. 9.2 years, p=0.03) (Table 1). Patients with suspected BE had higher
mean BMI (23.0 vs. 19.1, p=0.05) and reported significantly more chest pain (50% vs. 15%,
p<0.01) than patients without BE or RE. While dysphagia, epigastric pain heartburn, and
regurgitation were more frequent in patients with suspected BE than patients without BE or
RE, the differences were not statistically significant. Multivariate analysis was not
conducted given the low number of suspected BE cases.
A total of 216 patients (25.7%, 95% CI: 18.0–22.4) had RE. Of those, only 16 patients had
erosions seen endoscopically while the rest had histological esophagitis. The mean age of
patients with RE was 10.1 (SD 5.0) years. Patients with RE reported significantly more chest
pain (20% vs. 13%, p<0.01), dysphagia (19% vs. 10%, p<0.01), epigastric pain (79% vs.
66%, p<0.01), heartburn (38% vs. 28%, p=0.01), and regurgitation (38% vs. 26%, p<0.01)
than patients without BE or RE (Table 2). The association between RE and dysphagia and
epigastric pain remained statistically significant in a multivariable analysis that adjusted for
age, BMI, fundoplication, and the other upper gastrointestinal symptoms (aspiration, chest
pain, heartburn, regurgitation, vomiting, or poor weight gain).
Discussion
In this large, prospective, multicenter study of children and adolescents presenting for upper
endoscopy, we found that BE is rare in children without neurodevelopmental delay or
tracheoesophageal anomalies. The prevalence of endoscopically suspected BE was 1.41%,
and was reduced to 0.12% if histologic finding of intestinal metaplasia was also considered.
The prevalence of RE (25.7%), on the other hand, is much higher and approaches the
prevalence of RE in the adult population.16
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The very low prevalence of BE in children without neurodevelopmental delay or
tracheoesophageal anomalies affirms previous retrospective studies. Collectively, these
studies also confirm that congenital BE is very rare or nonexistent. In two separate studies
among different patient populations, we reported the prevalence of endoscopically suspected
BE in children without neurodevelopmental delay or tracheoesophageal anomalies to be
between 0.25% and 2.7%.5, 9 While different explanations (to the reported low BE
prevalence in children) related to endoscopic recognition of land marks have been posited,
11, 17 this study with its prospective design, standard definition of landmarks, and quality
control measures should allay these concerns. Larger prospective studies, with stricter or
different definition of landmarks and more extensive biopsy protocols may result in slightly
different BE prevalence estimates, however, we believe that the question has been answered
for this type of population. The findings however cannot be generalized to general pediatric
population or to patients with neurodevelopmental delay.
Despite the high prevalence of GERD symptoms as evidenced by approximately 42.7% of
the study population reporting heartburn or regurgitation and 88.6% reporting at least some
upper GI symptom, the prevalence of endoscopic BE was very low, much lower than the
expected rates in adults with similar symptoms.18–20 This suggests that duration of
symptoms and or age related effects are important risk factors for BE. Studies in adults
indicate that long duration of GERD symptoms is a significant risk factor for BE.21, 22
There were several cases in our current study where endoscopic BE was reported but
intestinal metaplasia was not found on histological examination of biopsies obtained from
these areas. This finding is consistent with previous studies.5, 8, 9 While sampling error may
be a possible explanation, another explanation may be that these areas of endoscopic BE
become populated with intestinal metaplasia at a later time. At this time, it is difficult to
make a firm recommendation regarding the prognosis or follow up of these patients.
The power to examine potential risk factors for BE was very limited for the very few cases
of suspected BE and virtually non existent for the only one confirmed BE case.
Nevertheless, obesity was a weak risk factor for suspected BE. While we cannot exclude
type 1 error, this might be a finding worth pursuing. Given the obesity epidemic in children,
it is possible the prevalence of BE would be higher in the future in children. Given the rare
occurrence of BE in the pediatric population any study of the characteristics of pediatric BE
would require a large multicenter study over many years.
Our study showed that the prevalence of RE was 25.7%, but only 16 of 840 patients (0.02%)
had erosions seen endoscopically while the rest had histological esophagitis. While we were
careful not to classify patients in whom eosinophil count was greater than 15 per high power
field as eosinophilic esophagitis rather than RE, we could have misclassified cases of
eosinophilic esophagitis that were well controlled with treatment at that time. The low
prevalence of erosions on endoscopy is different from two previous studies that examined
the prevalence of erosive esophagitis in children, which report the prevalence of endoscopic
erosive esophagitis to be 12.4% and 34.6%.5, 10 The difference in prevalence of endoscopic
erosive esophagitis could be due to the lack of standard scoring system for esophagitis or it
could be due to the real changes in the prevalence of endoscopic esophagitis secondary to
the changes in prescribing practice of proton pump inhibitors (PPIs) and histamine H2-
receptor antagonist (H2RA). The prior studies by El-Serag et al. and Gilger et al. examined
patients who underwent upper endoscopy during 1996–2000 and 1999–2001, instead the
current study examines patients during 2006–2007 where PPIs may more readily available.
We did not systematically collect information on the use of medications and therefore could
not ascertain the use of PPI, H2RA, or other medications that could be used to treat other
esophageal disorders such as eosinophilic esophagitis.
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In summary, we have shown in a large multicenter prospective study that suspected BE is
rare (and confirmed BE is very rare) in children and adolescent without neurodevelopmental
delay or tracheoesophageal anomalies.
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Endoscopic picture of the one patient with confirmed Barrett's esophagus based on
endoscopic finding (C0M1) and histologic finding of specialized intestinal epithelium.
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Table 1
Characteristics of the Cohort by Disease Category (Suspected Barrett’s esophagus (BE), reflux esophagitis
(RE), or neither)
Suspected BE N=12 # (%) RE N=216 # (%) Neither N=612 # (%) p-value* (general association)
Age
 Mean (sd), yrs 11.3 (4.5) 10.1 (5.0) 9.2 (5.3) 0.03
 Median 12.5 11.0 10.0
 0–5 yrs 2 (17) 45 (21) 175 (29)
 6–12 yrs 4 (33) 83 (38) 228 (37)
 13+ yrs 6 (50) 88 (41) 209 (34)
BMI
 Mean (sd) 23.0 (7.2) 19.0 (5.6) 19.1 (5.4) 0.05
 Median 22.8 18.0 17.6
Tobacco Use 1 (8) 1 (0) 0 (0) <0.01
Endoscopic Signs
 Erosions 2 (17) 10 (5) 0 (0) <0.01
 Hiatal Hernia 1 (8) 6 (3) 18 (3) 0.54
 Nodularity 0 (0) 13 (6) 18 (3) 0.09
 Ulceration 0 (0) 6 (3) 0 (0) <0.01
*
p-values for general associations were calculated as 2-sided using Chi-square tests, Fisher’s exact test, or ANOVA with an asterisk indicating
significance at the 0.05 level.
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